Company: PRME
Filing Date: 2025-04-22
Form Type: DEF 14A
Source: 0001628280-25-018704
Chunk: 28

Company: Prime Medicine, Inc.
Filing Date: 2025-04-22
Form: DEF 14A
Chunk 28
---
 exercised in connection with the timing of equity award grants. We also do not time the release of material nonpublic information based on equity award grant dates.

During the fiscal year ended December 31, 2024, we did not award any stock options to a named executive officer in the period beginning four business days before the filing of a periodic report on Form 10-Q or Form 10-K, or the filing or furnishing of a current report on Form 8-K that disclosed material nonpublic information, and ending one business day after the filing or furnishing of such report.

#### Communication with Directors
Any stockholders desiring to communicate with our Board, or one or more of our directors, may send a letter addressed to the Board of Directors of Prime Medicine, Inc., 60 First Street, Cambridge, MA 02141. All such letters will be promptly forwarded to the appropriate members of our Board or individual directors, as applicable.

<div align='center'>17</div>

#### Director Compensation
The following table presents the total compensation for each person who served as a non-employee member of our Board during the fiscal year ended December 31, 2024. Other than as set forth in the table and described more above, we did not pay any compensation, make any equity awards or non-equity awards to, or pay any other compensation to any of the non-employee members of our Board during the fiscal year ended December 31, 2024. We reimburse non-employee members of our Board for reasonable travel and out-of-pocket expenses incurred in attending meetings of our Board and committees of our Board. Dr. Gottesdiener, who is our Chief Executive Officer, did not receive any additional compensation for his service as a director. The compensation received by Dr. Gottesdiener, as an NEO of the Company, is presented in the “2024 Summary Compensation Table” below.

| Name                           |     | Fees Earned     
 or Paid in Cash 
 ($) (1)         |        |     | Option Awards 
 ($) (2)       |           |     | All Other    
 Compensation 
 ($)          |        |     | Total 
 ($)   |           |
| Thomas Cahill, M.D., Ph.D. (3) |     |                 | 57,188 |     |               |   237,528 |     |              |      — |     |       |   294,716 |
| Wendy Chung, M.D., Ph.D. (3)   |     |                 |